Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients

S. Weinstein, M. White, J. Corren, H. Nolte (Huntington Beach, Wheaton, Los Angeles, Kenilworth, United States Of America)

Source: Annual Congress 2009 - Towards improving asthma control
Session: Towards improving asthma control
Session type: E-Communication Session
Number: 280
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Weinstein, M. White, J. Corren, H. Nolte (Huntington Beach, Wheaton, Los Angeles, Kenilworth, United States Of America). Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients. Eur Respir J 2009; 34: Suppl. 53, 280

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function
Source: Eur Respir J 2012; 39: 279-289
Year: 2012



Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017


Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012


A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial
Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Year: 2012

Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011

Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004

Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010

Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Fluticasone/salmeterol combination (FP/S) for immediate post-exacerbation treatment of childhood asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013